Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Exploratory Clinical Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Autologous BCMA-targeted CAR-T Cell Injection in Participants With Relapsed/Refractory Light Chain Amyloidosis

NCT07626476 is registered in ClinicalTrials.gov with Beijing Boren Hospital as lead sponsor.

NCT NCT07626476
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07626476 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Exploratory Clinical Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Autologous BCMA-targeted CAR-T Cell Injection in Participants With Relapsed/Refractory Light Chain Amyloidosis
Lead sponsor
Beijing Boren Hospital
Phase
Phase 1
Overall status
Withdrawn
Start date
December 16, 2024
Completion date
December 15, 2029
Enrollment
0 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

al amyloidosis, relapsed/refractory light chain amyloidosis, systemic light chain amyloidosis